Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Rhea-AI Summary

Creative Medical Technology Holdings (NASDAQ: CELZ) announced positive two-year follow-up results from its StemSpine® study, demonstrating an 87% efficacy rate in treating chronic lower back pain. The procedure, using the patient's bone marrow aspirate, reported no serious adverse effects up to two years post-treatment. The company emphasizes this may help address the opioid crisis by offering a non-surgical option for millions suffering from chronic pain.

Positive

• 87% efficacy rate for pain reduction and mobility improvement reported in StemSpine® study.
• No serious adverse effects noted in patients up to two years post-treatment.
• Potential to address the opioid crisis by providing a non-surgical alternative for chronic lower back pain.

Negative

• None.

--Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients who Underwent the StemSpine® Procedure for Treating Chronic Lower Back Pain --

PHOENIX, Sept. 26, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, today announced the peer reviewed publication of positive, two-year follow-up data for the Company's StemSpine^® study, showing significant efficacy of the StemSpine^® procedure for treating chronic lower back pain without any serious adverse effects reported.

The StemSpine^® publication demonstrates the clinical use of the patented procedure that utilizes a patient's own bone marrow aspirate for the treatment of chronic lower back pain. There were no safety related concerns at up to two years follow-up. The StemSpine^® procedure resulted in an efficacy rate of 87% in the treated patients in terms of decreased pain and increased mobility.

"The positive two-year data from our StemSpine^® study is very encouraging and may help alleviate the current opioid crisis related to prescription medication abuse for chronic lower back pain," said Timothy Warbington, President and CEO of the Company. "To our knowledge, this is the first demonstration of the clinical efficacy of injecting bone marrow aspirate into areas surrounding the disc, which may repair, remodel and improve the blood supply around the disc and lower back area. We believe StemSpine^® represents an attractive non-surgical option for many of the millions of Americans who suffer from chronic lower back pain and look forward to further translation."

The StemSpine^® patent also covers the use of off the shelf adult donor stem cells (allogeneic) for this indication.

The publication may be found at www.creativemedicaltechnology.com.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a biotechnology company specializing in regenerative medicine in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. For further information about the Company, please visit www.creativemedicaltechnology.com. 

Forward Looking Statements

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

View original content to download multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-announces-peer-reviewed-publication-of-positive-results-for-stemspine-study-301632695.html

SOURCE Creative Medical Technology Holdings, Inc.

FAQ

What are the two-year follow-up results for the StemSpine® study by CELZ?

The two-year follow-up results show an 87% efficacy rate in treating chronic lower back pain with no serious adverse effects reported.

How does the StemSpine® procedure work?

The StemSpine® procedure utilizes a patient's own bone marrow aspirate to treat chronic lower back pain.

What was the publication date of the StemSpine® study results for CELZ?

The results were published on September 26, 2022.

What is the significance of the StemSpine® procedure according to CELZ?

The procedure may offer a non-surgical alternative for millions suffering from chronic lower back pain and could help alleviate the opioid crisis.